BC008 / Guilin SanJin Group - LARVOL DELTA

Sanyou Bio congratulates Dragon Boat Pharmaceutical on the approval of clinical trials of anti-CLDN18.2 antibody drug BC008 (PRNewswire) - "On April 1, Dragon Boat Pharmaceutical announced that its self-developed anti-CLDN18.2 antibody injection (BC008) had obtained the implied approval for clinical trials from China's National Medical Products Administration, and will be used for the clinical trials in the treatment of CLDN18.2-positive advanced malignant solid tumors....The preclinical study data of BC008 antibody injection shows that the drug can specifically target and bind CLDN18.2 molecules on the cell surface, and can play an anti-tumor role by specifically killing CLDN18.2-positive tumor cells through Fc-mediated immune effector functions such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC)."

New trial • Preclinical • Oncology • Solid Tumor